Adagene (ADAG)
(Delayed Data from NSDQ)
$2.98 USD
-0.01 (-0.34%)
Updated Jun 7, 2024 03:47 PM ET
After-Market: $2.92 -0.06 (-2.01%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADAG 2.98 -0.01(-0.34%)
Will ADAG be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for ADAG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADAG
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?
Are Medical Stocks Lagging Medpace (MEDP) This Year?
ADAG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Adagene (ADAG) This Year?
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
Other News for ADAG
12 Health Care Stocks Moving In Friday's After-Market Session
Adagene to Present at Investor Conferences in June
Analysts Offer Insights on Healthcare Companies: eFFECTOR Therapeutics (EFTR), Adagene (ADAG) and Aquestive Therapeutics (AQST)
12 Health Care Stocks Moving In Monday's Intraday Session
Adagene ADR Non-GAAP EPS of -$0.21, revenue of $18.11M